Cargando…
Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial
BACKGROUND: High-permeability pulmonary edema is a hallmark of acute respiratory distress syndrome (ARDS) and is frequently accompanied by impaired alveolar fluid clearance (AFC). AP301 enhances AFC by activating epithelial sodium channels (ENaCs) on alveolar epithelial cells, and we investigated it...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531100/ https://www.ncbi.nlm.nih.gov/pubmed/28750677 http://dx.doi.org/10.1186/s13054-017-1795-x |
_version_ | 1783253343290785792 |
---|---|
author | Krenn, Katharina Lucas, Rudolf Croizé, Adrien Boehme, Stefan Klein, Klaus Ulrich Hermann, Robert Markstaller, Klaus Ullrich, Roman |
author_facet | Krenn, Katharina Lucas, Rudolf Croizé, Adrien Boehme, Stefan Klein, Klaus Ulrich Hermann, Robert Markstaller, Klaus Ullrich, Roman |
author_sort | Krenn, Katharina |
collection | PubMed |
description | BACKGROUND: High-permeability pulmonary edema is a hallmark of acute respiratory distress syndrome (ARDS) and is frequently accompanied by impaired alveolar fluid clearance (AFC). AP301 enhances AFC by activating epithelial sodium channels (ENaCs) on alveolar epithelial cells, and we investigated its effect on extravascular lung water index (EVLWI) in mechanically ventilated patients with ARDS. METHODS: Forty adult mechanically ventilated patients with ARDS were included in a randomized, double-blind, placebo-controlled trial for proof of concept. Patients were treated with inhaled AP301 (n = 20) or placebo (0.9% NaCl; n = 20) twice daily for 7 days. EVLWI was measured by thermodilution (PiCCO®), and treatment groups were compared using the nonparametric Mann–Whitney U test. RESULTS: AP301 inhalation was well tolerated. No differences in mean baseline-adjusted change in EVLWI from screening to day 7 were found between the AP301 and placebo group (p = 0.196). There was no difference in the PaO(2)/FiO(2) ratio, ventilation pressures, Murray lung injury score, or 28-day mortality between the treatment groups. An exploratory subgroup analysis according to severity of illness showed reductions in EVLWI (p = 0.04) and ventilation pressures (p < 0.05) over 7 days in patients with initial sequential organ failure assessment (SOFA) scores ≥11 inhaling AP301 versus placebo, but not in patients with SOFA scores ≤10. CONCLUSIONS: There was no difference in mean baseline-adjusted EVLWI between the AP301 and placebo group. An exploratory post-hoc subgroup analysis indicated reduced EVLWI in patients with SOFA scores ≥11 receiving AP301. These results suggest further confirmation in future clinical trials of inhaled AP301 for treatment of pulmonary edema in patients with ARDS. TRIAL REGISTRATION: The study was prospectively registered at clinicaltrials.gov, NCT01627613. Registered 20 June 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-017-1795-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5531100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55311002017-08-02 Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial Krenn, Katharina Lucas, Rudolf Croizé, Adrien Boehme, Stefan Klein, Klaus Ulrich Hermann, Robert Markstaller, Klaus Ullrich, Roman Crit Care Research BACKGROUND: High-permeability pulmonary edema is a hallmark of acute respiratory distress syndrome (ARDS) and is frequently accompanied by impaired alveolar fluid clearance (AFC). AP301 enhances AFC by activating epithelial sodium channels (ENaCs) on alveolar epithelial cells, and we investigated its effect on extravascular lung water index (EVLWI) in mechanically ventilated patients with ARDS. METHODS: Forty adult mechanically ventilated patients with ARDS were included in a randomized, double-blind, placebo-controlled trial for proof of concept. Patients were treated with inhaled AP301 (n = 20) or placebo (0.9% NaCl; n = 20) twice daily for 7 days. EVLWI was measured by thermodilution (PiCCO®), and treatment groups were compared using the nonparametric Mann–Whitney U test. RESULTS: AP301 inhalation was well tolerated. No differences in mean baseline-adjusted change in EVLWI from screening to day 7 were found between the AP301 and placebo group (p = 0.196). There was no difference in the PaO(2)/FiO(2) ratio, ventilation pressures, Murray lung injury score, or 28-day mortality between the treatment groups. An exploratory subgroup analysis according to severity of illness showed reductions in EVLWI (p = 0.04) and ventilation pressures (p < 0.05) over 7 days in patients with initial sequential organ failure assessment (SOFA) scores ≥11 inhaling AP301 versus placebo, but not in patients with SOFA scores ≤10. CONCLUSIONS: There was no difference in mean baseline-adjusted EVLWI between the AP301 and placebo group. An exploratory post-hoc subgroup analysis indicated reduced EVLWI in patients with SOFA scores ≥11 receiving AP301. These results suggest further confirmation in future clinical trials of inhaled AP301 for treatment of pulmonary edema in patients with ARDS. TRIAL REGISTRATION: The study was prospectively registered at clinicaltrials.gov, NCT01627613. Registered 20 June 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-017-1795-x) contains supplementary material, which is available to authorized users. BioMed Central 2017-07-27 /pmc/articles/PMC5531100/ /pubmed/28750677 http://dx.doi.org/10.1186/s13054-017-1795-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Krenn, Katharina Lucas, Rudolf Croizé, Adrien Boehme, Stefan Klein, Klaus Ulrich Hermann, Robert Markstaller, Klaus Ullrich, Roman Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial |
title | Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial |
title_full | Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial |
title_fullStr | Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial |
title_full_unstemmed | Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial |
title_short | Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial |
title_sort | inhaled ap301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase iia randomized placebo-controlled trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531100/ https://www.ncbi.nlm.nih.gov/pubmed/28750677 http://dx.doi.org/10.1186/s13054-017-1795-x |
work_keys_str_mv | AT krennkatharina inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial AT lucasrudolf inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial AT croizeadrien inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial AT boehmestefan inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial AT kleinklausulrich inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial AT hermannrobert inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial AT markstallerklaus inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial AT ullrichroman inhaledap301fortreatmentofpulmonaryedemainmechanicallyventilatedpatientswithacuterespiratorydistresssyndromeaphaseiiarandomizedplacebocontrolledtrial |